熱門詞： 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥
Micromet 德國Micromet?
Micromet創建于德國，總部現設在馬里蘭州的Rockville，該公司正在開發一款試驗性血癌治療藥物，目前處在中期試驗階段。
Micromet was founded in 1993 by a small team of entrepreneurial scientists from the University of Munich with a firm belief in the potential of T cell based therapies to treat cancer. Their vision was to develop a new class of drugs that mobilize T cells, the body's most potent killer cells, enabling them to detect and destroy normally unrecognizable cancer cells. Within a few short years, the Company demonstrated the clinical potential of its technology, referred to as BiTE? (Bi-specific T cell engager), with the publication of compelling results from a Phase 1 trial of its BiTE antibody Blinatumomab (MT103) in patients with non-Hodgkin's lymphoma. Micromet began trading on the Nasdaq Global Market under the symbol MITI following a May 2006 reverse merger with California-based CancerVax.
Today Micromet is an integrated biopharmaceutical company with a pipeline of promising drug candidates, a clinically validated technology platform and strong BiTE antibody partnerships with industry leaders.
Micromet Today
Our goal is to discover, develop and commercialize breakthrough therapies with the potential to deliver meaningful clinical benefit to oncology patients. Our lead product candidate blinatumomab (MT103) has demonstrated single-agent activity in both adult and pediatric patients with acute lymphoblastic leukemia and is now the subject of a broad based development program in this disease setting. MT110, our second BiTE antibody, is currently in development in patients with advanced solid tumors. We are also advancing a pipeline of promising preclinical candidates and have robust research capabilities fuelling our long-term growth.
Micromet is headquartered in Rockville, Maryland with a research facility in Munich, Germany.
?
知識產權侵權投訴：不生產任何產品所有產品均來自產品的生產廠商、代理商、經銷商，如有侵權請聯系：400-006-7520 ，我們會在第一時間處理
本網站所有產品與藥品無關
滬公網安備31011502016460號
